trial
as of 2026-07-01Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
NCTId NCT06627413
at a glance
Phase 1 · Completed
Enrollment 52 (actual)
Sponsored by Intra-Cellular Therapies, Inc.
Primary completion 2025-11-20
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
52 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2024-08-23
Primary completion
2025-11-20
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Sponsors
Intra-Cellular Therapies, Inc.Lead Sponsor
Sites
4 total
Los Alamitos, United StatesAtlanta, United StatesDecatur, United StatesMarlton, United States
Facts & assertions
4 sourced
Enrollment
52
Phase
PHASE1
Primary Completion Date
2025-11-20
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
indication
indication
indication